At the beginning of 2025, good news keeps coming. The two products, Selethru® PTCA Balloon Dilatation Catheter and Selethru® NC PTCA Balloon Dilatation Catheter independently developed by Kossel, were approved for listing in Pakistan at the end of 2024 and then approved for listing by the Central Drugs Standard Control Organization (CDSCO) of India.

India is the most populous country in the world and one of the largest medical device markets in Asia. With the growth of the population base and rapid economic development, the market capacity of PCI will continue to maintain a high - growth trend. The approval for the listing of Selethru® PTCA Balloon Dilatation Catheter and Selethru® NC PTCA Balloon Dilatation Catheter in India this time will bring a better surgical experience to local surgeons. At the same time, it will also help the company further expand into the Asian market and bring new hope to more patients.

 Up to now, Selethru® PTCA Balloon Dilatation Catheter has been launched successively in Asia, the Middle East, and South America. Falspeed® PTA Balloon Dilatation Catheter has also been approved for marketing in the United States, the Middle East, Syria, Hong Kong (China), Ecuador, Brazil and other countries and regions. Thanks to its differentiated clinical layout and excellent clinical performance, it has benefited local doctors and patients.

In the future, we will continue to implement the "going - global" internationalization strategy, and work hand in hand with our partners to provide high - quality medical devices from China to more overseas patients.